8-K filed March 28, 2024, 7:59 PM ET ticker AVTX CIK 0001534120

M&A confidence high sentiment positive materiality 0.85

Avalo Therapeutics, Inc. (AVTX): M&A transaction — Avalo acquires Phase 2-ready anti-IL-1β mAb via merger with AlmataBio, raises $115.6M PIPE

Avalo Therapeutics, Inc.

Acquired AlmataBio for ~$15M in stock (171,605 common shares + 2,412 Series C Preferred), plus up to $27.5M in milestones.
Concurrent PIPE of $115.6M upfront (up to $185M total) led by Commodore Capital and TCGX; net proceeds ~$105M.
Lead asset AVTX-009 (anti-IL-1β mAb, ex-Eli Lilly) is Phase 2-ready for hidradenitis suppurativa; topline data expected 2026.
Cash runway extended into 2027; board expanded to 9 with appointments of Jonathan Goldman, Aaron Kantoff, Samantha Truex.

item 1.01 item 5.03 item 2.01 item 3.01 item 3.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Aaron Kantoff

Director

AVTX · Avalo Therapeutics, Inc.

Effective: 2024-03-28
Filed: March 28, 2024, 7:59 PM ET

the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024

Appointed

Jonathan Goldman

Director

AVTX · Avalo Therapeutics, Inc.

Effective: 2024-03-28
Filed: March 28, 2024, 7:59 PM ET

Jonathan Goldman was appointed to the Board.

Appointed

Samantha Truex

Director

AVTX · Avalo Therapeutics, Inc.

Effective: 2024-03-28
Filed: March 28, 2024, 7:59 PM ET

the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Aaron Kantoff was appointed as Director at Avalo Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Goldman was appointed as Director at Avalo Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Jonathan Goldman was appointed to the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Samantha Truex was appointed as Director at Avalo Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Avalo Therapeutics, Inc. completed an acquisition involving AlmataBio, Inc. for 171,605 shares of Common Stock and 2,412 shares of Series C Preferred Stock valued at approximately $15 million (closed 2024-03-27).

Action: acquisition
Counterparty: AlmataBio, Inc.
Consideration: 171,605 shares of Common Stock and 2,412 shares of Series C Preferred Stock valued at approximately $15 million
Closing: 2024-03-27

Exact text from the filing

or employee of the Company or the Subsidiary following completion of the Merger. As consideration for the Merger, the Company issued to the Almata stockholders an aggregate of 171,605 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and an aggregate of 2,412 shares of Series C Preferred Stock (as defined and described in

View on SEC.gov

68 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-013435

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.